Artene SA, Turcu-Stiolica A, Ciurea ME, Folcuti C, Tataranu LG, Alexandru O, Purcaru OS, Tache DE, Boldeanu MV, Silosi C and Dricu A: Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: A meta-analysis of published clinical trials. Sci Rep. 8(11800)2018.PubMed/NCBI View Article : Google Scholar

van Elsas MJ, van Hall T and van der Burg SH: Future challenges in cancer resistance to immunotherapy. Cancers (Basel). 12(935)2020.PubMed/NCBI View Article : Google Scholar

Oprita A and Sevastre AS: New pharmaceutical dosage forms used in the treatment of breast cancer. Polymeric micelles. Medico Oncol. 1:38–52. 2020.

Sevastre AS, Baloi SC, Cioc CE and Oprita A: New pharmaceutical dosage forms used in the treatment of breast cancer. Liposomes. Medico Oncol. 2:10–24. 2021.

Cosaceanu D, Carapancea M, Alexandru O, Budiu R, Martinsson HS, Starborg M, Vrabete M, Kanter L, Lewensohn R and Dricu A: Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro. Growth Factors. 25:1–8. 2007.PubMed/NCBI View Article : Google Scholar

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 17 (Suppl 4):iv1–iv62. 2015.PubMed/NCBI View Article : Google Scholar

Kleihues P and Cavenee W: Tumours of the nervous system: World Health Organization classification of tumours. IARC Press, Lyon, 2000.

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al: The somatic genomic landscape of glioblastoma. Cell. 155:462–477. 2013.PubMed/NCBI View Article : Google Scholar

Zhang J, Stevens MF and Bradshaw TD: Temozolomide: Mechanisms of action, repair and resistance. Curr Mol Pharmacol. 5:102–114. 2012.PubMed/NCBI View Article : Google Scholar

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.PubMed/NCBI View Article : Google Scholar

Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J and Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 5:79–88. 2003.PubMed/NCBI View Article : Google Scholar

Chiocca EA, Aguilar LK, Bell SD, Kaur B, Hardcastle J, Cavaliere R, McGregor J, Lo S, Ray-Chaudhuri A, Chakravarti A, et al: Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol. 29:3611–3619. 2011.PubMed/NCBI View Article : Google Scholar

Vollmann-Zwerenz A, Leidgens V, Feliciello G, Klein CA and Hau P: Tumor cell invasion in glioblastoma. Int J Mol Sci. 21(1932)2020.PubMed/NCBI View Article : Google Scholar

Fernandes C, Costa A, Osório L, Lago RC, Linhares P, Carvalho B and Caeiro C: Current standards of care in glioblastoma therapy. In: Glioblastoma. De Vleeschouwer S (ed). Codon Publications, Brisbane, AU, Chapter 11, 2017.

Lee SY: Temozolomide resistance in glioblastoma multiforme. Genes Dis. 3:198–210. 2016.PubMed/NCBI View Article : Google Scholar

Alves AL, Gomes IN, Carloni AC, Rosa MN, da Silva LS, Evangelista AF, Reis RM and Silva VA: Role of glioblastoma stem cells in cancer therapeutic resistance: A perspective on antineoplastic agents from natural sources and chemical derivatives. Stem Cell Res Ther. 12(206)2021.PubMed/NCBI View Article : Google Scholar

Fleurence J, Bahri M, Fougeray S, Faraj S, Vermeulen S, Pinault E, Geraldo F, Oliver L, Véziers J, Marquet P, et al: Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside. Int J Cancer. 146:424–438. 2020.PubMed/NCBI View Article : Google Scholar

Horescu C, Elena Cioc C, Tuta C, Sevastre AS, Tache DE, Alexandru O, Artene SA, Danoiu S, Dricu A and Stefana Oana P: The effect of temozolomide in combination with doxorubicin in glioblastoma cells in vitro. J Immunoassay Immunochem. 41:1033–1043. 2020.PubMed/NCBI View Article : Google Scholar

Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, et al: Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. J Clin Oncol. 32: (Suppl 15)(S2020)2014.PubMed/NCBI View Article : Google Scholar

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, et al: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): A randomised, open-label, phase 3 trial. Lancet. 393:678–688. 2019.PubMed/NCBI View Article : Google Scholar

Parrozzani R, Lombardi G, Midena E, Londei D, Padovan M, Marchione G, Caccese M, Midena G, Zagonel V and Frizziero L: Ocular side effects of EGFR-inhibitor ABT-414 in recurrent glioblastoma: A long-term safety study. Front Oncol. 10(593461)2020.PubMed/NCBI View Article : Google Scholar

Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M and Choulier L: A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers (Basel). 13(1795)2021.PubMed/NCBI View Article : Google Scholar

Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R and Glantz M: Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis. JAMA Oncol. 2:1460–1469. 2016.PubMed/NCBI View Article : Google Scholar

Alexandru O, Horescu C, Sevastre AS, Cioc CE, Baloi C, Oprita A and Dricu A: Receptor tyrosine kinase targeting in glioblastoma: Performance, limitations and future approaches. Contemp Oncol (Pozn). 24:55–66. 2020.PubMed/NCBI View Article : Google Scholar

Kleinberg L: Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: Patient selection and perspectives on a low-burden therapy. Patient Prefer Adherence. 10:2397–2406. 2016.PubMed/NCBI View Article : Google Scholar

Thirupathy A, Srinivas P, Babu DS and Mamidi S: Formulation and evaluation of sustained release implantable microspheres of temozolomide for brain targeting prepared by a novel technique. Int J Pharm Pharm Sci. 3:187–194. 2011.

Lam FC, Morton SW, Wyckoff J, Vu Han TL, Hwang MK, Maffa A, Balkanska-Sinclair E, Yaffe MB, Floyd SR and Hammond PT: Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 9(1991)2018.PubMed/NCBI View Article : Google Scholar

Fang C, Wang K, Stephen ZR, Mu Q, Kievit FM, Chiu DT, Press OW and Zhang M: Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Interfaces. 7:6674–6682. 2015.PubMed/NCBI View Article : Google Scholar

Ramalho MJ, Sevin E, Gosselet F, Lima J, Coelho MAN, Loureiro JA and Pereira MC: Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. Int J Pharm. 545:84–92. 2018.PubMed/NCBI View Article : Google Scholar

Bertucci A, Prasetyanto EA, Septiadi D, Manicardi A, Brognara E, Gambari R, Corradini R and De Cola L: Combined delivery of temozolomide and anti-miR221 PNA using mesoporous silica nanoparticles induces apoptosis in resistant glioma Cells. Small. 11:5687–5695. 2015.PubMed/NCBI View Article : Google Scholar

Irani M, Mir Mohamad Sadeghi G and Haririan I: A novel biocompatible drug delivery system of chitosan/temozolomide nanoparticles loaded PCL-PU nanofibers for sustained delivery of temozolomide. Int J Biol Macromol. 97:744–751. 2017.PubMed/NCBI View Article : Google Scholar

Gürten B, Yenigül E, Sezer AD, Altan C and Malta S: Targeting of temozolomide using magnetic nanobeads: An in vitro study. Braz J Pharm Sci. 56:2020.

Chakravarty M, Ganguli P, Murahari M, Sarkar RR, Peters GJ and Mayur YC: Study of combinatorial drug synergy of novel acridone derivatives with temozolomide using in-silico and in-vitro methods in the treatment of drug-resistant glioma. Front Oncol. 11(625899)2021.PubMed/NCBI View Article : Google Scholar

Artene SA, Tuţă C, Dragoi A, Alexandru O, Stefana Oana P, Tache DE, Dănciulescu MM, Boldeanu MV, Siloşi CA and Dricu A: Current and emerging EGFR therapies for glioblastoma. J Immunoassay Immunochem. 39:1–11. 2018.PubMed/NCBI View Article : Google Scholar

Alexandru O, Purcaru SO, Tataranu LG, Lucan L, Castro J, Folcuţi C, Artene SA, Tuţă C and Dricu A: The influence of EGFR inactivation on the radiation response in high grade glioma. Int J Mol Sci. 19(229)2018.PubMed/NCBI View Article : Google Scholar

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J and Khasraw M: Anti-angiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 11(CD008218)2018.PubMed/NCBI View Article : Google Scholar

Dietrich J, Wang D and Batchelor TT: Cediranib: Profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs. 18:1549–1557. 2009.PubMed/NCBI View Article : Google Scholar

Hyman DM, Rizvi N, Natale R, Armstrong DK, Birrer M, Recht L, Dotan E, Makker V, Kaley T, Kuruvilla D, et al: Phase I study of MEDI3617, a selective angiopoietin-2 inhibitor alone and combined with carboplatin/paclitaxel, paclitaxel, or bevacizumab for advanced solid tumors. Clin Cancer Res. 24:2749–2757. 2018.PubMed/NCBI View Article : Google Scholar

Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, Sparidans RW, Beijnen JH, Würdinger T and van Tellingen O: PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models. Clin Cancer Res. 23:1286–1298. 2017.PubMed/NCBI View Article : Google Scholar

Popescu AM, Alexandru O, Brindusa C, Purcaru SO, Tache DE, Tataranu LG, Taisescu C and Dricu A: Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment. Int J Clin Exp Pathol. 8:7825–7837. 2015.PubMed/NCBI

Purcaru SO, Tache DE, Serban F, Folcuti RM, Georgescu AM, Stovicek PO, Danciulescu MM, Tataranu LG and Dricu A: Effect of VEGFR, PDGFR and PI3K/mTOR targeting in glioblastoma. Curr Health Sci J. 41:325–332. 2015.PubMed/NCBI View Article : Google Scholar

Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA and Stathopoulos A: First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine. 33:2690–2696. 2015.PubMed/NCBI View Article : Google Scholar

Wahl LM and Pattenden T: Prophage provide a safe haven for adaptive exploration in temperate viruses. Genetics. 206:407–416. 2017.PubMed/NCBI View Article : Google Scholar

Geletneky K, Hajda J, Angelova A, Leuchs B, Capper D, Bartsch AJ, Neumann JO, Schöning T, Hüsing J, Beelte B, et al: Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. Mol Ther. 25(2620)2017.PubMed/NCBI View Article : Google Scholar

Vatu BI, Artene SA, Staicu AG, Turcu-Stiolica A, Folcuti C, Dragoi A, Cioc C, Baloi SC, Tataranu LG, Silosi C and Dricu A: Assessment of efficacy of dendritic cell therapy and viral therapy in high grade glioma clinical trials. A meta-analytic review. J Immunoassay Immunochem. 40:70–80. 2019.PubMed/NCBI View Article : Google Scholar

Satterlee AB, Dunn DE, Lo DC, Khagi S and Hingtgen S: Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma. Neuro Oncol. 21:1552–1564. 2019.PubMed/NCBI View Article : Google Scholar

Ciurea ME, Georgescu AM, Purcaru SO, Artene SA, Emami GH, Boldeanu MV, Tache DE and Dricu A: Cancer stem cells: Biological functions and therapeutically targeting. Int J Mol Sci. 15:8169–8185. 2014.PubMed/NCBI View Article : Google Scholar

Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008.PubMed/NCBI View Article : Google Scholar

Liu S, Tang Y, Yuan X, Yuan D, Liu J, Li B and Li Y: Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells. Invest New Drugs. 36:961–969. 2018.PubMed/NCBI View Article : Google Scholar

Forte IM, Indovina P, Iannuzzi CA, Cirillo D, Di Marzo D, Barone D, Capone F, Pentimalli F and Giordano A: Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int J Oncol. 54:2189–2199. 2019.PubMed/NCBI View Article : Google Scholar

Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, et al: A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol. 126:185–192. 2016.PubMed/NCBI View Article : Google Scholar

Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL and de Groot JF: Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. Neuro Oncol. 18:1230–1241. 2016.PubMed/NCBI View Article : Google Scholar

Payton M, Jun T, Wayne W, Yu D, Manoukian R, Chung G, Zhang N, Sun JR, Kaplan-Lefko P, Scully S, et al: Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method. Lab Invest. 94:1296–1308. 2014.PubMed/NCBI View Article : Google Scholar

Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, et al: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 28:1168–1174. 2010.PubMed/NCBI View Article : Google Scholar

Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, et al: First-in-human phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. Clin Cancer Res. 26:1820–1828. 2020.PubMed/NCBI View Article : Google Scholar

Maklad A, Sharma A and Azimi I: Calcium signaling in brain cancers: Roles and therapeutic targeting. Cancers (Basel). 11(145)2019.PubMed/NCBI View Article : Google Scholar

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E and Adolf GR: Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 343:342–350. 2012.PubMed/NCBI View Article : Google Scholar

Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, et al: Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Res. 76:2432–2442. 2016.PubMed/NCBI View Article : Google Scholar

Stylli SS: Novel treatment strategies for glioblastoma. Cancers (Basel). 12(2883)2020.PubMed/NCBI View Article : Google Scholar

Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O'Rourke DM, D'Ambrosio A, Bruce JN and Parsa AT: Autologous heat shock protein peptide vaccination for newly diagnosed glioblastoma: impact of peripheral PD-L1 expression on response to therapy. Clin Cancer Res. 23:3575–3584. 2017.PubMed/NCBI View Article : Google Scholar

Krendyukov A and Gieffers C: Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies. Cancer Manag Res. 11:8095–8100. 2019.PubMed/NCBI View Article : Google Scholar

von Achenbach C, Silginer M, Blot V, Weiss WA and Weller M: Depatuxizumab mafodotin (ABT-414)-induced glioblastoma cell death requires EGFR overexpression, but not EGFR^Y1068 phosphorylation. Mol Cancer Ther. 19:1328–1339. 2020.PubMed/NCBI View Article : Google Scholar

Lukas RV, Juhász C, Wainwright DA, James CD, Kennedy E, Stupp R and Lesniak MS: Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. J Neurooncol. 141:111–120. 2019.PubMed/NCBI View Article : Google Scholar

Angelova AL, Barf M, Geletneky K, Unterberg A and Rommelaere J: Immunotherapeutic potential of oncolytic H-1 parvovirus: Hints of glioblastoma microenvironment conversion towards immunogenicity. Viruses. 15(382)2017.PubMed/NCBI View Article : Google Scholar

Alphandéry E: Glioblastoma treatments: An account of recent industrial developments. Front Pharmacol. 9(879)2018.PubMed/NCBI View Article : Google Scholar

Łata S and Molczyk A: Side effects of temozolomide treatment in patient with glioblastoma multiforme-case study. Przegl Lek. 67:445–446. 2010.PubMed/NCBI(In Polish).

Sabel M and Giese A: Safety profile of carmustine wafers in malignant glioma: A review of controlled trials and a decade of clinical experience. Curr Med Res Opin. 24:3239–3257. 2008.PubMed/NCBI View Article : Google Scholar

Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, et al: Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 377:1954–1963. 2017.PubMed/NCBI View Article : Google Scholar

Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, et al: Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro Oncol. 19:845–852. 2017.PubMed/NCBI View Article : Google Scholar

Alshami J, Guiot MC, Owen S, Kavan P, Gibson N, Solca F, Cseh A, Reardon DA and Muanza T: Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report. Oncotarget. 6:34030–34037. 2015.PubMed/NCBI View Article : Google Scholar

Clinical Trials: National Library of Medicine: Safety Study of VAL-083 in patients with recurrent malignant glioma. Available from: https://clinicaltrials.gov/ct2/show/NCT01478178. Accessed August 5, 2021.

Mamo A, Baig A, Azam M, Rho YS, Sahebjam S, Muanza T, Owen S, Petrecca K, Guiot MC, Al-Shami J, et al: Progression pattern and adverse events with bevacizumab in glioblastoma. Curr Oncol. 23:e468–e471. 2016.PubMed/NCBI View Article : Google Scholar

Odia Y, Sul J, Shih JH, Kreisl TN, Butman JA, Iwamoto FM and Fine HA: A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. CNS Oncol. 5:59–67. 2016.PubMed/NCBI View Article : Google Scholar

Swartz AM, Li QJ and Sampson JH: Rindopepimut: A promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy. 6:679–690. 2014.PubMed/NCBI View Article : Google Scholar

Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, Mechtler LR, Belal A, Ahluwalia MS and Hutson AD: Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 65:1339–1352. 2016.PubMed/NCBI View Article : Google Scholar

Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, et al: A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res. 22:4776–4785. 2016.PubMed/NCBI View Article : Google Scholar

Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, et al: A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res. 25:5799–5807. 2019.PubMed/NCBI View Article : Google Scholar

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, et al: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 16(142)2018.PubMed/NCBI View Article : Google Scholar

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, et al: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5(e8)2008.PubMed/NCBI View Article : Google Scholar

Whittle JR, Lickliter JD, Gan HK, Scott AM, Simes J, Solomon BJ, MacDiarmid JA, Brahmbhatt H and Rosenthal MA: First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J Clin Neurosci. 22:1889–1894. 2015.PubMed/NCBI View Article : Google Scholar

Philbrick BD and Adamson DC: Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. Expert Opin Investig Drugs. 28:207–216. 2019.PubMed/NCBI View Article : Google Scholar

Chiocca EA, Yu J, Lukas RV, Buck J, Demars N, Barrett J, Yang Y, Cooper L and Lebel F: ATIM-26. A phase 1 study of AD-RTS-HIL-12 + veledimex in adult recurrent glioblastoma. Neuro Oncol. 19 (Suppl 6)(vi32)2017.

Zuccarini M, Giuliani P, Ziberi S, Carluccio M, Iorio PD, Caciagli F and Ciccarelli R: The role of Wnt signal in glioblastoma development and progression: A possible new pharmacological target for the therapy of this tumor. Genes (Basel). 9(105)2018.PubMed/NCBI View Article : Google Scholar

Peñaranda-Fajardo NM, Meijer C, Liang Y, Dijkstra BM, Aguirre-Gamboa R, den Dunnen WFA and Kruyt FAE: ER stress and UPR activation in glioblastoma: Identification of a noncanonical PERK mechanism regulating GBM stem cells through SOX2 modulation. Cell Death Dis. 10(690)2019.PubMed/NCBI View Article : Google Scholar

European Medicines Agency: COVID-19 pandemic. Available from: www.ema.europa.eu. Accessed September 5, 2021.

Günther W, Pawlak E, Damasceno R, Arnold H and Terzis AJ: Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer. 88:463–469. 2003.PubMed/NCBI View Article : Google Scholar

Darlix A, Baumann C, Lorgis V, Ghiringhelli F, Blonski M, Chauffert B, Zouaoui S, Pinelli C, Rech F, Beauchesne P and Taillandier L: Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res. 33:3467–3474. 2013.PubMed/NCBI

Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, Simmet T, Corbacioglu S and Debatin KM: RIST: A potent new combination therapy for glioblastoma. Int J Cancer. 136:E173–E187. 2015.PubMed/NCBI View Article : Google Scholar

Halatsch ME, Kast RE, Dwucet A, Hlavac M, Heiland T, Westhoff MA, Debatin KM, Wirtz CR, Siegelin MD and Karpel-Massler G: Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. Br J Pharmacol. 176:3681–3694. 2019.PubMed/NCBI View Article : Google Scholar

Affronti ML, Heery CR, Herndon JE II, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD and Friedman HS: Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 115:3501–3511. 2009.PubMed/NCBI View Article : Google Scholar

Clinical Trials: National Library of Medicine: O6-benzylguanine-mediated tumor sensitization with chemoprotected autologous stem cell in treating patients with malignant gliomas. Available from: https://clinicaltrials.gov/ct2/show/NCT00669669?term=carmustine&recrs=d&cond=glioblastoma&draw=2&rank=1. Accessed February 25, 2021.

National Library of Medicine: National Center for Biotechnology Information: Lomustine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Lomustine. Accessed February 25, 2021.

Reimunde P, Pensado-López A, Carreira Crende M, Lombao Iglesias V, Sánchez L, Torrecilla-Parra M, Ramírez CM, Anfray C and Torres Andón F: Cellular and molecular mechanisms underlying glioblastoma and zebrafish models for the discovery of new treatments. Cancers (Basel). 13(1087)2021.PubMed/NCBI View Article : Google Scholar

Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, et al: Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 17:430–439. 2015.PubMed/NCBI View Article : Google Scholar

Vengoji R, Macha MA, Nimmakayala RK, Rachagani S, Siddiqui JA, Mallya K, Gorantla S, Jain M, Ponnusamy MP, Batra SK and Shonka N: Afatinib and temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J ExpClin Cancer Res. 38(266)2019.PubMed/NCBI View Article : Google Scholar

Oprita A, Baloi SC, Staicu GA, Alexandru O, Tache DE, Danoiu S, Micu ES and Sevastre AS: Updated insights on EGFR signaling pathways in glioma. Int J Mol Sci. 22(587)2021.PubMed/NCBI View Article : Google Scholar

Clinical Trials: National Library of Medicine. Available from: https://clinicaltrials.gov/. Accessed April 5, 2021.

Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, Christner SM, Komaki R, DeAngelis LM, Gaur R, et al: Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 17:992–998. 2015.PubMed/NCBI View Article : Google Scholar

Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, et al: Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 20:110–119. 2019.PubMed/NCBI View Article : Google Scholar

Stehman FB, Blom J, Blessing JA, Ehrlich CE and Mangan C: Phase II trial of galactitol 1,2:5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: A gynecologic oncology group study. Gynecol Oncol. 15:381–390. 1983.PubMed/NCBI View Article : Google Scholar

O'Brien B, Groot J, Kamiya-Matsuoka C, Weathers SP, Bacha J, Brown D, Steino A, Langlands J, Schwartz R, Kanekal S, et al: ACTR-27. Phase 2 study of dianhydrogalactitol (val-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma. Neuro Oncol. 20 (Suppl 6)(vi17)2018.

Keir ST, Friedman HS, Reardon DA, Bigner DD and Gray LA: Mibefradil, a novel therapy for glioblastoma multiforme: Cell cycle synchronization and interlaced therapy in a murine model. J Neurooncol. 111:97–102. 2013.PubMed/NCBI View Article : Google Scholar

Lester-Coll NH, Supko JG, Kluytenaar J, Pavlik KF, Yu JB, Moliterno J, Piepmeier J, Becker K, Baehring JM, Huttner A, et al: Mibefradil dihydrochoride with hypofractionated radiation for recurrent glioblastoma: A phase I dose expansion trial. J Clin Oncol. 36 (Suppl 15)(e14046)2018.

Clinical Trials: National Library of Medicine. Available from: https://clinicaltrials.gov/ct2/results?cond=glioblastoma&term=mibefradil&cntry=&state=&city=&dist=. Accessed February 20, 2021.

Wang N, Jain RK and Batchelor TT: New Directions in anti-angiogenic therapy for glioblastoma. Neurotherapeutics. 14:321–332. 2017.PubMed/NCBI View Article : Google Scholar

Arbab AS: Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol Histopathol. 27:549–557. 2012.PubMed/NCBI View Article : Google Scholar

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009.PubMed/NCBI View Article : Google Scholar

Lu G, Rao M, Zhu P, Liang B, El-Nazer RT, Fonkem E, Bhattacharjee MB and Zhu JJ: Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: A retrospective study. Front Neurol. 10(42)2019.PubMed/NCBI View Article : Google Scholar

Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, et al: A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/north central cancer treatment group N0872. Cancer. 125:3790–3800. 2019.PubMed/NCBI View Article : Google Scholar

Akiyode O and Dunkelly-Allen N: Ranibizumab: A review of its use in the treatment of diabetic retinopathy in patients with diabetic macular edema. J Pharm Technol. 32:22–28. 2016.

Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S and Supko JG: Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro Oncol. 19:567–575. 2017.PubMed/NCBI View Article : Google Scholar

Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, et al: Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 31:3212–3218. 2013.PubMed/NCBI View Article : Google Scholar

Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, et al: Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA. 110:19059–19064. 2013.PubMed/NCBI View Article : Google Scholar

Odia Y, Iwamoto FM, Moustakas A, Fraum TJ, Salgado SA, Li A, Kreisl TN, Sul J, Butman JA and Fine HA: A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas. J Neuro Oncol. 127:127–135. 2016.PubMed/NCBI View Article : Google Scholar

Clinical Trials: A Trial of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma with or without the novel genomic biomarker, DGM1. Available from: https://clinicaltrials.gov/ct2/show/NCT03776071. Accessed January 15, 2021.

Limeta A, Ji B, Levin M, Gatto F and Nielsen J: Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. JCI Insight. 5(e140940)2020.PubMed/NCBI View Article : Google Scholar

Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD and Goldhirsch A: Cancer immunotherapy efficacy and patients' sex: A systematic review and meta-analysis. Lancet Oncol. 19:737–746. 2018.PubMed/NCBI View Article : Google Scholar

Tarantino P, Gandini S, Trapani D, Criscitiello C and Curigliano G: Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 159(103223)2021.PubMed/NCBI View Article : Google Scholar

Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, Phuphanich S, de Souza P, Ahluwalia MS, Lim M, et al: Os10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: Checkmate 143. Neuro Oncol. 19 (Suppl 3)(iii21)2017.

Clinical Trials: National Library of Medicine: Available from: https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=immunotherapy&cntry=&state=&city=&dist=. Accessed September 3, 2021.

Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R and Carpentier AF: Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer. 73:1–8. 2017.PubMed/NCBI View Article : Google Scholar

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al: Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol. 18:1373–1385. 2017.PubMed/NCBI View Article : Google Scholar

Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, et al: A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 17:854–861. 2015.PubMed/NCBI View Article : Google Scholar

Wood CG and Mulders P: Vitespen: A preclinical and clinical review. Future Oncol. 5:763–774. 2009.PubMed/NCBI View Article : Google Scholar

Clinical Trials: Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence. Available from: https://clinicaltrials.gov/ct2/show/NCT04013672?term=SurVaxM&cond=glioblastoma&draw=2&rank=1. Accessed April 5, 2021.

Migliorini D and Dutoit V: ATIM-21. IMA950 peptide-based vaccine adjuvanted with poly-ICLC in combination with standard therapy in newly diagnosed HLA-A2 glioblastoma patients: Preliminary results. Neuro Oncol. 18 (Suppl 6)(vi22)2016.

Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T and Yang WK: A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci. 18:1048–1054. 2011.PubMed/NCBI View Article : Google Scholar

Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, et al: Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 62:125–135. 2013.PubMed/NCBI View Article : Google Scholar

Wick W and van den Bent MJ: First results on the DCVax phase III trial: Raising more questions than providing answers. Neuro Oncol. 20:1283–1284. 2018.PubMed/NCBI View Article : Google Scholar

Polyzoidis S and Ashkan K: DCVax^®-L-developed by Northwest Biotherapeutics. Hum Vaccin Immunother. 10:3139–3145. 2014.PubMed/NCBI View Article : Google Scholar

Van Gool SW, Makalowski J, Fiore S, Sprenger T, Prix L, Schirrmacher V and Stuecker W: Randomized controlled immunotherapy clinical trials for GBM challenged. Cancers (Basel). 13(32)2020.PubMed/NCBI View Article : Google Scholar

Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, et al: A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res. 20:6304–6313. 2014.PubMed/NCBI View Article : Google Scholar

Wick W, Krendyukov A, Junge K, Höger T and Fricke H: Longitudinal analysis of quality of life following treatment with asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients. J Neurooncol. 145:531–540. 2019.PubMed/NCBI View Article : Google Scholar

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, et al: Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: Results from an international phase I multicenter trial. Neuro Oncol. 21:106–114. 2019.PubMed/NCBI View Article : Google Scholar

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, et al: Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: Results from a multi-center, international study. Cancer Chemother Pharmacol. 80:1209–1217. 2017.PubMed/NCBI View Article : Google Scholar

Phuphanich S, Raizer J, Chamberlain M, Canelos P, Narwal R, Hong S, Miday R, Nade M and Laubscher K: Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma. J Neurooncol. 131:185–191. 2017.PubMed/NCBI View Article : Google Scholar

Caster JM, Patel AN, Zhang T and Wang A: Investigational nanomedicines in 2016: A review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 9:2017.PubMed/NCBI View Article : Google Scholar

Mozhei O, G Teschemacher A and Kasparov S: Viral vectors as gene therapy agents for treatment of glioblastoma. Cancers (Basel). 12(3724)2020.PubMed/NCBI View Article : Google Scholar

Banerjee K, Núñez FJ, Haase S, McClellan BL, Faisal SM, Carney SV, Yu J, Alghamri MS, Asad AS, Candia AJN, et al: Current approaches for glioma gene therapy and virotherapy. Front Mol Neurosci. 14(621831)2021.PubMed/NCBI View Article : Google Scholar

Caffery B, Lee JS and Alexander-Bryant AA: Vectors for glioblastoma gene therapy: Viral & non-viral delivery strategies. Nanomaterials (Basel). 9(105)2019.PubMed/NCBI View Article : Google Scholar

Rubsam LZ, Boucher PD, Murphy PJ, KuKuruga M and Shewach DS: Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 59:669–675. 1999.PubMed/NCBI

Clinical Trials: Gene Therapy for the Treatment of Brain Tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT00001328. Accessed January 20, 2021.

Ji N, Weng D, Liu C, Gu Z, Chen S, Guo Y, Fan Z, Wang X, Chen J, Zhao Y, et al: Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget. 7:4369–4378. 2016.PubMed/NCBI View Article : Google Scholar

Clinical Trials: HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM. Available from: https://clinicaltrials.gov/ct2/show/NCT03603405.

Zadeh G, Bota D, Cachia D, Landolfi J, Schiff D, Vogelbaum MA, Walbert T, Tran D, Chu A, Das A, et al: PC3-151 Toca 5: A phase 2/3 randomized, open-label study of Toca 511, a retroviral replicating vector, combined with Toca FC versus standard of care in patients undergoing planned resection for recurrent glioblastoma (GBM) or anaplastic astrocytoma (AA) (NCT02414165). Can J NeurolSci. 43 (Suppl 4)(S17)2016.

Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, et al: Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 8(341ra75)2016.PubMed/NCBI View Article : Google Scholar

Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, et al: Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. Sci Transl Med. 11(eaaw5680)2019.PubMed/NCBI View Article : Google Scholar

Clinical Trials: Study of Ad-RTS-hIL-12 + veledimex in combination with cemiplimab in subjects with recurrent or progressive glioblastoma. Available from: https://clinicaltrials.gov/ct2/show/NCT04006119. Accessed February 3, 2021.

Kim SS, Rait A, Kim E, Pirollo KF and Chang EH: A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine. 11:301–311. 2015.PubMed/NCBI View Article : Google Scholar

Clinical Trials: Phase II study of combined temozolomide and SGT-53 for treatment of recurrent glioblastoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02340156. Accessed February 3, 2021.

Kumthekar P, Rademaker A, Ko C, Dixit K, Schwartz MA, Sonabend AM, Sharp L, Vincas Lukas R, Stupp R, Horbinski C, et al: A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients. J Clin Oncol. 37 (Suppl 15)(S3012)2019.

Lacroix J, Leuchs B, Li J, Hristov G, Deubzer HE, Kulozik AE, Rommelaere J, Schlehofer JR and Witt O: Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. Int J Cancer. 127:1230–1239. 2010.PubMed/NCBI View Article : Google Scholar

Sevastre AS, Horescu C, Baloi CS, Cioc CE, Vatu BI, Tuta C, Artene SA, Danciulescu MM, Tudorache S and Dricu A: Benefits of nanomedicine for therapeutic intervention in malignant diseases. Coatings. 9(628)2019.

Carapancea M, Alexandru O, Fetea AS, Dragutescu L, Castro J, Georgescu A, Popa-Wagner A, Bäcklund ML, Lewensohn R and Dricu A: Growth factor receptors signaling in glioblastoma cells: Therapeutic implications. J Neurooncol. 92:137–147. 2009.PubMed/NCBI View Article : Google Scholar

Alexandru O, Dragutescu L, Tataranu L, Ciubotaru V, Sevastre A, Georgescu AM, Purcaru O, Danoiu S, Bäcklund LM and Dricu A: Helianthin induces antiproliferative effect on human glioblastoma cells in vitro. J Neurooncol. 102:9–18. 2011.PubMed/NCBI View Article : Google Scholar

Alexandru O, Sevastre AS, Castro J, Artene SA, Tache DE, Purcaru OS, Sfredel V, Tataranu LG and Dricu A: Platelet-derived growth factor receptor and ionizing radiation in high grade glioma cell lines. Int J Mol Sci. 20(4663)2019.PubMed/NCBI View Article : Google Scholar

Sevastre AS, Buzatu IM, Baloi C, Oprita A, Dragoi A, Tataranu LG, Alexandru O, Tudorache S and Dricu A: ELTD1-an emerging silent actor in cancer drama play. Int J Mol Sci. 22(5151)2021.PubMed/NCBI View Article : Google Scholar

Weyerhäuser P, Kantelhardt SR and Kim EL: Re-purposing chloroquine for glioblastoma: Potential merits and confounding variables. Front Oncol. 8(335)2018.PubMed/NCBI View Article : Google Scholar

Mazurek M, Litak J, Kamieniak P, Kulesza B, Jonak K, Baj J and Grochowski C: Metformin as potential therapy for high-grade glioma. Cancers (Basel). 12(210)2020.PubMed/NCBI View Article : Google Scholar

Karamanakos PN, Trafalis DT, Papachristou DJ, Panteli ES, Papavasilopoulou M, Karatzas A, Kardamakis D, Nasioulas G and Marselos M: Evidence for the efficacy of disulfiram and copper combination in glioblastoma multiforme-A propos of a case. J BUON. 22:1227–1232. 2017.PubMed/NCBI

Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, et al: Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 12:1300–1310. 2010.PubMed/NCBI View Article : Google Scholar

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, et al: Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American brain tumor consortium trial 04-02. Neuro Oncol. 16:567–578. 2014.PubMed/NCBI View Article : Google Scholar

Clinical Trials: Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01051557. Accessed August 1, 2021.

Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE II, Marcello J, Norfleet JA, McLendon RE, Sampson JH and Friedman HS: Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 96:219–230. 2010.PubMed/NCBI View Article : Google Scholar

Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, et al: Vandetanib plus sirolimus in adults with recurrent glioblastoma: Results of a phase I and dose expansion cohort study. J Neurooncol. 121:627–634. 2015.PubMed/NCBI View Article : Google Scholar

Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, Rosenfeld MR, Mikkelsen T and Grossman SA: New Approaches to Brain Tumor Therapy Consortium. NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 15:490–496. 2013.PubMed/NCBI View Article : Google Scholar

Sousa F, Moura RP, Moreira E, Martins C and Sarmento B: Therapeutic monoclonal antibodies delivery for the glioblastoma treatment. Adv Protein Chem Struct Biol. 112:61–80. 2018.PubMed/NCBI View Article : Google Scholar

Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, et al: Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 159:647–661. 2014.PubMed/NCBI View Article : Google Scholar

Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS and Cloughesy T: Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemother Pharmacol. 84:327–336. 2019.PubMed/NCBI View Article : Google Scholar

Damore MA, Coberly SK, Wakamiya K, Webster S, Tanna V, Xu X, Klement I, Welcher R, Kiaei P, Liu Y, et al: An EGFRvIII-specific IHC IUO test for patient selection in AMG 595 phase I trial. J Clin Oncol. 31 (Suppl 15)(S2071)2013.

Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, et al: AMG 595, an anti-EGFRvIII antibody-drug conjugate, induces potent antitumor activity against EGFRvIII-expressing glioblastoma. Mol Cancer Ther. 14:1614–1624. 2015.PubMed/NCBI View Article : Google Scholar

Diaz-Miqueli A, Blanco R, Lemm M, Fichtner I, León K and Montero E: Preclinical efficacy of nimotuzumab, an anti-EGFR monoclonal antibody as a single agent therapy in human GBM U87MG xenografts. J Cancer Ther. 3:245–255. 2012.

Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domíngez R, Alert J, Marinello JJ, et al: Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: Results from a randomized, double blind trial. BMC Cancer. 13(299)2013.PubMed/NCBI View Article : Google Scholar

Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, et al: A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 51:522–532. 2015.PubMed/NCBI View Article : Google Scholar

Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, et al: Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol Cancer Ther. 14:1141–1151. 2015.PubMed/NCBI View Article : Google Scholar

Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, et al: Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro Oncol. 20:838–847. 2018.PubMed/NCBI View Article : Google Scholar

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004.PubMed/NCBI View Article : Google Scholar

Chadwick M, Huselid E, Bartucci M, Patrizii M, Jara K, Mehta M, Gilleran J, Augeri D and Sabaawy H: Abstract 3073: Development of novel BMI1 inhibitors targeting glioblastoma stem-like cells abstract. Cancer Res. 79 (Suppl 13)(S3073)2019.

Affinito A, Quintavalle C, Esposito CL, Roscigno G, Vilardo C, Nuzzo S, Vitiani LR, De Luca G, Minic Z, Giannetti S, et al: 1998P-The discovery of RNA-aptamers that selectively bind and inhibit glioblastoma stem cells by targeting EphA2. Ann Oncol. 30(v802)2019.PubMed/NCBI View Article : Google Scholar

Kouri FM, Ritner C and Stegh AH: miRNA-182 and the regulation of the glioblastoma phenotype-toward miRNA-based precision therapeutics. Cell Cycle. 14:3794–3800. 2015.PubMed/NCBI View Article : Google Scholar

Johnston MJ, Nikolic A, Ninkovic N, Guilhamon P, Cavalli FMG, Seaman S, Zemp FJ, Lee J, Abdelkareem A, Ellestad K, et al: High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. Genome Res. 29:1211–1222. 2019.PubMed/NCBI View Article : Google Scholar

Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N, Winchester E, Spencer J, et al: Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science. 280:1077–1082. 1998.PubMed/NCBI View Article : Google Scholar

Fisher JP and Adamson DC: Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 9(324)2021.PubMed/NCBI View Article : Google Scholar

Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, et al: Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 104:10152–10157. 2007.PubMed/NCBI View Article : Google Scholar

Frenster JD, Desai S and Placantonakis DG: In vitro evidence for glioblastoma cell death in temperatures found in the penumbra of laser-ablated tumors. Int J Hyperthermia. 37:20–26. 2020.PubMed/NCBI View Article : Google Scholar

Rennert RC, Khan U, Bartek J, Tatter SB, Field M, Toyota B, Fecci PE, Judy K, Mohammadi AM, Landazuri P, et al: Laser ablation of abnormal neurological tissue using robotic neuroblate system (LAANTERN): Procedural safety and hospitalization. Neurosurgery. 86:538–547. 2020.PubMed/NCBI View Article : Google Scholar

Branter J, Basu S and Smith S: Tumour treating fields in a combinational therapeutic approach. Oncotarget. 9:36631–36644. 2018.PubMed/NCBI View Article : Google Scholar

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380:358–365. 2012.PubMed/NCBI View Article : Google Scholar

Peterson YK and Luttrell LM: The diverse roles of arrestin scaffolds in G protein-coupled receptor signaling. Pharmacol Rev. 69:256–297. 2017.PubMed/NCBI View Article : Google Scholar

DeWire SM, Kim J, Whalen EJ, Ahn S, Chen M and Lefkowitz RJ: Beta-arrestin-mediated signaling regulates protein synthesis. J Biol Chem. 283:10611–10620. 2008.PubMed/NCBI View Article : Google Scholar

Artene SA, Folcuti C and Dricu A: β-arrestin 1 overexpression increases temozolomide resistance in human malignant glioma cells. Curr Health Sci J. 43:112–119. 2017.PubMed/NCBI View Article : Google Scholar

Horescu C and Artene SA: The effect of beta-arrestin 1 transfection on proliferation and temozolomide treatment response in HGG cells. Medico Oncol. 1:1–9. 2020.PubMed/NCBI View Article : Google Scholar

Blomquist MR, Ensign SF, D'Angelo F, Phillips JJ, Ceccarelli M, Peng S, Halperin RF, Caruso FP, Garofano L, Byron SA, et al: Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression. Neurooncol Adv. 2(vdaa078)2020.PubMed/NCBI View Article : Google Scholar

White K, Connor K, Clerkin J, Murphy BM, Salvucci M, O'Farrell AC, Rehm M, O'Brien D, Prehn JHM, Niclou SP, et al: New hints towards a precision medicine strategy for IDH wild-type glioblastoma. Ann Oncol. 31:1679–1692. 2020.PubMed/NCBI View Article : Google Scholar

Liu L, Wang G, Wang L, Yu C, Li M, Song S, Hao L, Ma L and Zhang Z: Computational identification and characterization of glioma candidate biomarkers through multi-omics integrative profiling. Biol Direct. 15(10)2020.PubMed/NCBI View Article : Google Scholar

Duan R, Gao L, Gao Y, Hu Y, Xu H, Huang M, Song K, Wang H, Dong Y, Jiang C, et al: Evaluation and comparison of multi-omics data integration methods for cancer subtyping. PLoS Comput Biol. 17(e1009224)2021.PubMed/NCBI View Article : Google Scholar

Popescu SO, Costachi A, Cioc CE, Buteica A and Dricu A: Iron oxide magnetic nanoparticles as drug delivery systems for brain cancer treatment. Medico Oncol. 2:55–66. 2021.

Saenz-Antoñanzas A, Auzmendi-Iriarte J, Carrasco-Garcia E, Moreno-Cugnon L, Ruiz I, Villanua J, Egaña L, Otaegui D, Samprón N and Matheu A: Liquid biopsy in glioblastoma: Opportunities, applications and challenges. Cancers (Basel). 11(950)2019.PubMed/NCBI View Article : Google Scholar